A

ActivMed Practices and Research | Portsmouth - Borthwick

Research site

(Unclaimed)

Location

155 Borthwick Ave Suite 250, Portsmouth, New Hampshire, United States of America

Site insights

Top conditions

Top treatments

Naltrexone Hydrochloride

Bupropion Hydrochloride

Aducanumab

ACU193

JNJ-77242113

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 6 total trials

A Study to Evaluate Efficacy and Safety of Intravenous ACU193 in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

The primary purpose of this study is to evaluate the efficacy of ACU193 infusions administered once every four weeks (Q4W) in slowing cognitive and f...

Enrolling

Alzheimer Disease

Drug: ACU193

Drug: Placebo

A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease (ENVISION)

The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment a...

Active, not recruiting

Alzheimer's Disease

Drug: Placebo

Drug: Aducanumab

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) (INFORMUS)

A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).

Enrolling

Obesity

Drug: Placebo

Drug: Naltrexone-Bupropion (NB) Combination

Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines (COVID-19)

This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent seve...

Active, not recruiting

COVID-19

Biological: NVX-CoV2601 (5μg)

Biological: NVX-CoV2601 (35μg)

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. (RENOIR)

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Active, not recruiting

Lower Respiratory Tract Illness

Biological: RSVpreF

Biological: Placebo